Literature DB >> 15289338

Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.

Pandurangan Ramaraj1, Harjeet Singh, Ning Niu, Su Chu, Melissa Holtz, Jiing Kuan Yee, Ravi Bhatia.   

Abstract

Chronic myelogenous leukemia (CML) results from transformation of a primitive hematopoietic cell by the BCR/ABL gene. The specific BCR/ABL signaling mechanisms responsible for transformation of primitive human hematopoietic cells are not well defined. Previous studies have suggested that constitutively activated tyrosine kinase activity plays an important role for in abnormal proliferation of CML progenitors but has not clearly defined its role in abnormal adhesion and migration. We established a human progenitor model of CML by ectopic expression of BCR/ABL in normal CD34+ cells using retrovirus-mediated gene transfer. CD34+ cells expressing BCR/ABL demonstrated several features characteristic of primary CML progenitors including increased proliferation in committed and primitive progenitor culture, reduced adhesion to fibronectin, and reduced chemotaxis to stroma-derived factor-1alpha. We expressed a kinase-inactive BCR/ABL gene to directly investigate the role of kinase activity in abnormal progenitor function. Abnormalities in proliferation were completely reversed, whereas defects in adhesion and migration were significantly improved but not completely reversed in cells expressing a kinase-inactive BCR/ABL. Furthermore, the BCR/ABL kinase inhibitor imatinib mesylate markedly inhibited proliferation of BCR/ABL-expressing progenitors but did not fully correct the adhesion and migration defects. Expression of BCR/ABL genes with deletions of either the COOH-terminal actin binding or proline-rich domains resulted in enhanced adhesion and chemotaxis compared with wild-type BCR/ABL but did not affect progenitor proliferation. We conclude that abnormal kinase activity is essential for abnormal proliferation and survival of CML progenitors but that abnormal adhesion and migration result from both kinase-dependent and -independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289338     DOI: 10.1158/0008-5472.CAN-03-3656

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription.

Authors:  Weiqi Huang; Wei Zhou; Gurveen Saberwal; Iwona Konieczna; Elizabeth Horvath; Efstratios Katsoulidis; Leonidas C Platanias; Elizabeth A Eklund
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

2.  Stem cell persistence in chronic myeloid leukemia.

Authors:  M Deininger
Journal:  Leuk Suppl       Date:  2012-08-09

3.  Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.

Authors:  Hongfeng Yuan; Zhiqiang Wang; Ling Li; Hao Zhang; Hardik Modi; David Horne; Ravi Bhatia; WenYong Chen
Journal:  Blood       Date:  2011-12-29       Impact factor: 22.113

Review 4.  Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Authors:  Thomas O'Hare; Matthew S Zabriskie; Anna M Eiring; Michael W Deininger
Journal:  Nat Rev Cancer       Date:  2012-07-24       Impact factor: 60.716

5.  BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.

Authors:  Hongfeng Yuan; Zhiqiang Wang; Chunggang Gao; Wengang Chen; Qin Huang; Jiing-Kuan Yee; Ravi Bhatia; WenYong Chen
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

6.  Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.

Authors:  Efstratios Katsoulidis; Antonella Sassano; Beata Majchrzak-Kita; Nathalie Carayol; Patrick Yoon; Alison Jordan; Brian J Druker; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

Review 7.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

8.  Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.

Authors:  S Chu; T McDonald; R Bhatia
Journal:  Leukemia       Date:  2010-03-04       Impact factor: 11.528

9.  The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.

Authors:  S Sahay; N L Pannucci; G M Mahon; P L Rodriguez; N J Megjugorac; E V Kostenko; H L Ozer; I P Whitehead
Journal:  Oncogene       Date:  2007-10-08       Impact factor: 9.867

Review 10.  Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.

Authors:  Christine Victoria Ichim
Journal:  Stem Cells Transl Med       Date:  2014-03-05       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.